-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, J5a9kGTBVHWZoTKe0clU9aB28O+jmncl9n3O9CzQHiHfDb97KUqEqggyQwYrtePv cJodWNBHJI9YNoPHYX/AdA== 0001104659-06-019435.txt : 20060327 0001104659-06-019435.hdr.sgml : 20060327 20060327150309 ACCESSION NUMBER: 0001104659-06-019435 CONFORMED SUBMISSION TYPE: 424B3 PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20060327 DATE AS OF CHANGE: 20060327 FILER: COMPANY DATA: COMPANY CONFORMED NAME: VERTEX PHARMACEUTICALS INC / MA CENTRAL INDEX KEY: 0000875320 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 043039129 STATE OF INCORPORATION: MA FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 424B3 SEC ACT: 1933 Act SEC FILE NUMBER: 333-120055 FILM NUMBER: 06711788 BUSINESS ADDRESS: STREET 1: 130 WAVERLY STREET CITY: CAMBRIDGE STATE: MA ZIP: 02139-4242 BUSINESS PHONE: 6165776000 424B3 1 a06-7734_1424b3.htm PROSPECTUS FILED PURSUANT TO RULE 424(B)(3)

 

Filed Pursuant to Rule 424(b)(3)

Registration No. 333-120055

 

PROSPECTUS SUPPLEMENT NO. 8 DATED MARCH 27, 2006

(TO PROSPECTUS DATED FEBRUARY 14, 2005)

 

VERTEX PHARMACEUTICALS INCORPORATED

 

$79,313,000 5 3¤4% Convertible Senior Subordinated Notes Due 2011

5,308,800 Shares of Common Stock Issuable Upon Conversion of the Notes

 

This Prospectus Supplement No. 8 supplements and amends the Prospectus dated February 14, 2005 (the “Prospectus”), relating to the resale from time to time by holders of our 5 3¤4% Convertible Senior Subordinated Notes Due 2011 (the “Notes”) (Restricted CUSIP: 92352FAG5; Registered CUSIP: 92352FAK6) and shares of our common stock issuable upon the conversion of the Notes. Such information has been obtained from the selling holders. This prospectus supplement should be read in conjunction with the Prospectus, which is to be delivered with this prospectus supplement.

 

The information appearing in the table below, as of the date hereof, supplements and amends the information in the table appearing under the heading “Selling Holders” in the Prospectus, and, where the name of a selling holder identified in the table below also appears in the table in the Prospectus, the information set forth in the table below regarding that selling holder supercedes the information in the Prospectus:

 

Name of security holder

 

Principal
Amount of
Notes
Beneficially
Owned and
Offered(1)

 

Number of shares
of Common Stock
Issuable Upon
Conversion of the
Notes
that May Be
Offered

 

Amaranth LLC

 

2,500,000

 

167,336

 

Amaranth Helix Limited

 

2,500,000

 

167,336

 

Bank Austria Cayman Islands Ltd.

 

3,493,000

 

233,802

 

BP Amoco PLC Master Trust

 

644,000

 

43,106

 

Consolidated Pension Plan

 

325,000

 

21,754

 

Context Convertible Arbitrage Fund, LP

 

2,800,000

 

187,417

 

Context Convertible Arbitrage Offshore LTD

 

7,690,000

 

514,726

 

Clinton Multistrategy Master Fund, Ltd.

 

4,000,000

 

267,738

 

Delaware Street Capital Master Fund L.P.

 

1,000,000

 

66,935

 

Detroit Medical Center Endowment/Funded Dep. Fund (and) The Detroit Medical Center Guggenheim Portfolio Co. XV, LLC

 

483,000

 

32,329

 

Estate of James Campbell CH

 

11,000

 

736

 

Estate of James Campbell EST2

 

212,000

 

14,190

 

Hotel Union & Hotel Industry of Hawaii Pension Plan

 

179,000

 

11,981

 

Institutional Benchmark Master Fund Ltd.

 

736,000

 

49,264

 

Institutional Benchmark Master Fund c/o Quattro Fund

 

1,307,000

 

87,484

 

National Bank of Canada

 

575,000

 

38,488

 

Quattro Fund Ltd.

 

15,552,000

 

1,040,964

 

Quattro Multistrategy Master Fund

 

541,000

 

36,212

 

QVT Fund LP(2)

 

10,437,000

 

698,595

 

Ramius, LP(3)

 

135,000

 

9,036

 

Ramius Capital Group(3)

 

645,000

 

43,173

 

 


-----END PRIVACY-ENHANCED MESSAGE-----